Literature DB >> 2317112

Neuropsychiatric lupus erythematosus, cerebral infarctions, and anticardiolipin antibodies.

R A Fields1, W L Sibbitt, H Toubbeh, A D Bankhurst.   

Abstract

Anticardiolipin antibody (aCL) has been associated with thromboembolic phenomena, including stroke, in certain patients with systemic lupus erythematosus (SLE); however, the relation between this antibody and the central nervous system manifestations of SLE is unknown. Serum samples and cerebrospinal fluid from five patients with SLE and acute central nervous system manifestations were assayed for the presence of aCL. Anticardiolipin antibody was identified in sera from four of the five patients but in none of the cerebrospinal fluid samples. Nuclear magnetic resonance imaging showed 'infarct-like' lesions in these four patients. This preliminary study suggests that a correlation between serum aCL and cerebral infarcts in central nervous system lupus may potentially exist. From this limited study it seems unlikely that aCL has a direct pathogenic role in the diffuse encephalopathy of acute central nervous system lupus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2317112      PMCID: PMC1003990          DOI: 10.1136/ard.49.2.114

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  28 in total

Review 1.  The natural history of systemic lupus erythematosus by prospective analysis.

Authors:  D Estes; C L Christian
Journal:  Medicine (Baltimore)       Date:  1971-03       Impact factor: 1.889

2.  Arterial thrombosis, intrauterine death and "lupus" antiocoagulant: detection of immunoglobulin interfering with prostacyclin formation.

Authors:  L O Carreras; G Defreyn; S J Machin; J Vermylen; R Deman; B Spitz; A Van Assche
Journal:  Lancet       Date:  1981-01-31       Impact factor: 79.321

3.  The pathogenesis of central nervous system manifestations of systemic lupus erythematosus.

Authors:  N J Zvaifler; H G Bluestein
Journal:  Arthritis Rheum       Date:  1982-07

4.  Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955--1977.

Authors:  S G Ellis; M A Verity
Journal:  Semin Arthritis Rheum       Date:  1979-02       Impact factor: 5.532

5.  Cerebral infarction associated with lupus anticoagulants--preliminary report.

Authors:  R G Hart; V T Miller; B M Coull; V Bril
Journal:  Stroke       Date:  1984 Jan-Feb       Impact factor: 7.914

6.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

7.  Thrombosis in patients with the lupus anticoagulant.

Authors:  J R Mueh; K D Herbst; S I Rapaport
Journal:  Ann Intern Med       Date:  1980-02       Impact factor: 25.391

8.  Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus.

Authors:  E N Harris; A E Gharavi; M L Boey; B M Patel; C G Mackworth-Young; S Loizou; G R Hughes
Journal:  Lancet       Date:  1983-11-26       Impact factor: 79.321

9.  Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations of systemic lupus erythematosus.

Authors:  H G Bluestein; G W Williams; A D Steinberg
Journal:  Am J Med       Date:  1981-02       Impact factor: 4.965

10.  The relationship between lupus anticoagulants and antibodies to phospholipid.

Authors:  D A Triplett; J T Brandt; K A Musgrave; C A Orr
Journal:  JAMA       Date:  1988 Jan 22-29       Impact factor: 56.272

View more
  9 in total

Review 1.  The antiphospholipid syndrome: a syndrome in evolution.

Authors:  R A Asherson; R Cervera
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

Review 2.  Current concepts of neuropsychiatric systemic lupus erythematosus (NP-SLE).

Authors:  R A Asherson; S D Denburg; J A Denburg; R M Carbotte; N Futrell
Journal:  Postgrad Med J       Date:  1993-08       Impact factor: 2.401

3.  Inhibition of astrocyte proliferation and binding to brain tissue of anticardiolipin antibodies purified from lupus serum.

Authors:  K H Sun; W T Liu; C Y Tsai; T S Liao; W M Lin; C L Yu
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

4.  A case of diffuse lupus encephalopathy successfully treated with high-dose intravenous methylprednisolone.

Authors:  G Di Iorio; U Picillo; P Santanelli; S Migliaresi; V Bonavita
Journal:  Ital J Neurol Sci       Date:  1992-04

5.  Abnormalities of magnetic resonance imaging of the central nervous system in patients with systemic lupus erythematosus correlate with disease severity.

Authors:  A Cauli; C Montaldo; M T Peltz; P Nurchis; G Sanna; P Garau; R Pala; G Passiu; A Mathieu
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

6.  Leukoencephalopathy and chronic pancreatitis as concomitant manifestations of systemic lupus erythematosus related to anticardiolipin antibodies.

Authors:  J Swol-Ben; C J Bruns; U Müller-Ladner; F Hofstädter; J Link; C Hechenrieder; K-W Jauch
Journal:  Rheumatol Int       Date:  2003-08-21       Impact factor: 2.631

7.  Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus.

Authors:  Michelle Petri; Mohammad Naqibuddin; Kathryn A Carson; Daniel J Wallace; Michael H Weisman; Stephen L Holliday; Margaret Sampedro; Shalini Narayana; Peter T Fox; Crystal Franklin; Patricia A Padilla; Robin L Brey
Journal:  J Rheumatol       Date:  2008-09-15       Impact factor: 4.666

8.  Neurological disease associated with anticardiolipin antibodies in patients without systemic lupus erythematosus: clinical and immunological features.

Authors:  A M Chancellor; R E Cull; D C Kilpatrick; C P Warlow
Journal:  J Neurol       Date:  1991-10       Impact factor: 4.849

Review 9.  Systemic lupus erythematosus: immunopathogenesis of neurologic dysfunction.

Authors:  P M Moore; R P Lisak
Journal:  Springer Semin Immunopathol       Date:  1995
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.